Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study

被引:17
作者
Wei, Fuqun [1 ]
Huang, Qizhen [2 ]
Zhou, Yang [1 ]
Luo, Liuping [1 ]
Zeng, Yongyi [1 ]
机构
[1] Fujian Med Univ, Mengchao Hepatobiliary Hosp, Dept Hepatopancreatobiliary Surg, Xihong Rd 312, Fuzhou 350025, Fujian, Peoples R China
[2] Fujian Med Univ, Mengchao Hepatobiliary Hosp, Dept Radiat Oncol, Fuzhou, Peoples R China
关键词
Recurrent hepatocellular carcinoma; Radiofrequency ablation; Repeat hepatectomy; Propensity-score matching; Subcapsular location; LAPAROSCOPIC HEPATECTOMY; LIVER RESECTION; SAFETY; CHEMOEMBOLIZATION; MANAGEMENT; OUTCOMES; IMPACT; RISK;
D O I
10.1186/s12957-021-02277-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundRepeat hepatectomy and radiofrequency ablation (RFA) are widely used to treat early recurrent hepatocellular carcinoma (RHCC) located in the subcapsular region, but the optimal treatment strategy remains to be controversial.MethodsA total of 126 RHCC patients in the subcapsular location after initial radical hepatectomy were included in this study between Dec 2014 and Jan 2018. These patients were divided into the RFA group (46 cases) and the repeat hepatectomy group (80 cases). The primary endpoints include repeat recurrence-free survival (rRFS) and overall survival (OS), and the secondary endpoint was complications. The propensity-score matching (PSM) was conducted to minimize the bias. Complications were evaluated using the Clavien-Dindo classification, and severe complications were defined as classification of complications of >= grade 3.ResultsThere were no significant differences in the incidence of severe complications were observed between RFA group and repeat hepatectomy group in rRFS and OS both before (1-, 2-, and 3-year rRFS rates were 65.2%, 47.5%, and 33.3% vs 72.5%, 51.2%, and 39.2%, respectively, P = 0.48; 1-, 2-, and 3-year OS rates were 93.5%, 80.2%, and 67.9% vs 93.7%, 75.8%, and 64.2%, respectively, P = 0.92) and after PSM (1-, 2-, and 3-year rRFS rates were 68.6%, 51.0%, and 34.0% vs 71.4%, 42.9%, and 32.3%, respectively, P = 0.78; 1-, 2-, and 3-year OS rates were 94.3%, 82.9%, and 71.4% vs 88.6%, 73.8%, and 59.0%, respectively, P = 0.36). Moreover, no significant differences in the incidence of severe complications were observed between the RFA group and repeat hepatectomy group.ConclusionBoth repeat hepatectomy and RFA are shown to be effective and safe for the treatment of RHCC located in the subcapsular region.
引用
收藏
页数:11
相关论文
共 41 条
[21]   Do hepatocellular carcinomas located in subcapsular space or in proximity to vessels increase the rate of local tumor progression? A meta-analysis [J].
Lai, Zhi-Cheng ;
Liang, Jin-Yu ;
Chen, Li-Da ;
Wang, Zhu ;
Ruan, Si-Min ;
Xie, Xiao-Yan ;
Lu, Ming-De ;
Hu, Hang-Tong ;
Wang, Wei .
LIFE SCIENCES, 2018, 207 :381-385
[22]   The Current Role of Radiofrequency Ablation in the Management of Hepatocellular Carcinoma A Systematic Review [J].
Lau, Wan Yee ;
Lai, Eric C. H. .
ANNALS OF SURGERY, 2009, 249 (01) :20-25
[23]   Serum metabolites may be useful markers to assess vascular invasion and identify normal alpha-fetoprotein in hepatocellular carcinoma undergoing liver resection: a pilot study [J].
Lee, Chao-Wei ;
Yu, Ming-Chin ;
Lin, Gigin ;
Chiu, Jo-Chu ;
Chiang, Meng-Han ;
Sung, Chang-Mu ;
Hsieh, Yi-Chung ;
Kuo, Tony ;
Lin, Cheng-Yu ;
Tsai, Hsin-, I .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
[24]   Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma: A Retrospective Study [J].
Liang, Hui-Hong ;
Chen, Min-Shan ;
Peng, Zhen-Wei ;
Zhang, Yao-Jun ;
Zhang, Ya-Qi ;
Li, Jin-Qing ;
Lau, Wan Yee .
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (12) :3484-3493
[25]   Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma [J].
Llovet, JM ;
Vilana, R ;
Brú, C ;
Bianchi, L ;
Salmeron, JM ;
Boix, L ;
Ganau, S ;
Sala, M ;
Pagès, M ;
Ayuso, C ;
Solé, M ;
Rodés, J ;
Bruix, R .
HEPATOLOGY, 2001, 33 (05) :1124-1129
[26]  
Medical Administration and Medical Administration Bureau of Health and Family Planning Commission of the People's Republic of China, 2020, CHIN J DIG SURY, V19, P1, DOI [10.3760/cma.j.issn.1673-9752.2020.01.001, DOI 10.3760/CMA.J.ISSN.1673-9752.2020.01.001]
[27]   Recurrent hepatocellular carcinoma: A Western strategy that emphasizes the impact of pathologic profile of the first resection [J].
Meniconi, Roberto L. ;
Komatsu, Shohei ;
Perdigao, Fabiano ;
Boelle, Pierre-Yves ;
Soubrane, Olivier ;
Scatton, Olivier .
SURGERY, 2015, 157 (03) :454-462
[28]   Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma [J].
Minagawa, M ;
Makuuchi, M ;
Takayama, T ;
Kokudo, N .
ANNALS OF SURGERY, 2003, 238 (05) :703-710
[29]   Hepatocellular carcinoma [J].
Oliveri, Roberto S. ;
Wetterslev, Jorn ;
Gluud, Christian .
LANCET, 2012, 380 (9840) :470-470
[30]   Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma [J].
Omata, Masao ;
Lesmana, Laurentius A. ;
Tateishi, Ryosuke ;
Chen, Pei-Jer ;
Lin, Shi-Ming ;
Yoshida, Haruhiko ;
Kudo, Masatoshi ;
Lee, Jeong Min ;
Choi, Byung Ihn ;
Poon, Ronnie T. P. ;
Shiina, Shuichiro ;
Cheng, Ann Lii ;
Jia, Ji-Dong ;
Obi, Shuntaro ;
Han, Kwang Hyub ;
Jafri, Wasim ;
Chow, Pierce ;
Lim, Seng Gee ;
Chawla, Yogesh K. ;
Budihusodo, Unggul ;
Gani, Rino A. ;
Lesmana, C. Rinaldi ;
Putranto, Terawan Agus ;
Liaw, Yun Fan ;
Sarin, Shiv Kumar .
HEPATOLOGY INTERNATIONAL, 2010, 4 (02) :439-474